Correlation between interleukin 10 and vascular endothelial growth factor expression in human esophageal cancer
Interleukin 10 (IL-10) is an immunosuppressive cytokine produced by T-lymphocytes, and is a regulatory molecule for angiogenesis in various cancers. We examined IL-10 and vascular endothelial growth factor (VEGF) gene expression in 45 esophageal cancer patients who underwent surgical
resection. Thirty-seven (82.2%) of the 45 esophageal cancers revealed IL-10 gene expression. VEGF121, VEGF165 and VEGF189 isoforms were detected in 93.3% (42/45), 55.6% (25/45) and 26.7% (12/45) of cases, respectively. IL-10 gene expression was significantly correlated with VEGF121 gene expression
(P=0.0039, Fisher's test). The results suggested that IL-10 stimulates angiogenic factor gene expression.
Document Type: Research Article
Affiliations: Department of Pathology, Tokai University School of Medicine, Bohseidai, Isehara-shi, Kanagawa 259-1193, Japan
Publication date: 01 August 2002
- The International Journal of Molecular Medicine is a monthly, peer-reviewed journal devoted to the publication of high quality studies related to the molecular mechanisms of human disease. The journal welcomes research on all aspects of molecular and clinical research, ranging from biochemistry to immunology, pathology, genetics, human genomics, microbiology, molecular pathogenesis, molecular cardiology, molecular surgery and molecular psychology.
The International Journal of Molecular Medicine aims to provide an insight for researchers within the community in regard to developing molecular tools and identifying molecular targets for the diagnosis and treatment of a diverse number of human diseases. - Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content